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REDUCTION IN MATERNAL AUTOANTIBODIES WITH INTRAVENOUS 
IMMUNOGLOBULIN THERAPY DURING PREGNANCY 
DANIELLE ROCHELEAU  
ABSTRACT 
 The prevalence of autoimmune lupus has increased with the onset of disease 
typically occurring during the women’s reproductive years. As a result, many women are 
experiencing obstetric complications associated with lupus, including neonatal lupus 
(NL) syndrome. In particular, pregnant women who have elevated anti-Ro/SSA 
antibodies carry an increased risk of developing NL syndrome with the most serious 
complication being congenital complete heard block (CHB). Currently, there is no 
effective treatment for CHB and affected children often require cardiac pacemakers if 
they survive past delivery.   
Recent studies have shown an association between the concentration of anti-
Ro/SSA antibodies and risk of fetal cardiac damage in NL. While the exact etiology of 
CHB is unknown, a therapeutic intervention aimed at reducing the concentration of these 
pathogenic antibodies may prevent the progression of cardiac NL in high risk 
pregnancies.  
This proposal is a pilot, double-blind, placebo-controlled randomized study 
assessing the effect of IVIG therapy on the change in concentration of maternal 
autoantibodies throughout pregnancy. Secondary outcomes will include 2nd and 3rd 
degree CHB. This study could potentially add to current evidence supporting the use of 
IVIG therapy in anti-Ro/SSA positive mothers to prevent the development of cardiac NL. 
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If efficacious, it would also provide clinicians a safe and cost-effective option for women 
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Systemic Lupus Erythematosus (SLE) is an autoimmune disease that primarily affects 
young females during their reproductive years. For many women with lupus, 
unpredictable flares make managing lupus during pregnancy especially challenging. 
These women are at increased risk of many obstetric complications, including fetal loss, 
preterm birth, intrauterine growth restriction (IUGR) and, most importantly, neonatal 
lupus syndrome.1 Neonatal lupus (NL) is an autoimmune disease characterized by passive 
transfer of autoantibodies from the mother to the fetus, leading to a variety of clinical 
manifestations. While it is common for only one organ system to be affected, NL can 
cause skin, cardiac, hepatobiliary or hematologic disease with cardiac disease being the 
most serious complication.2 Cardiac NL can include any degree of heart block with or 
without extranodal disease and typically occurs in utero during fetal development. While 
the pathogenesis is not entirely understood, it is hypothesized that autoantibodies, 
specifically anti-Ro/SSA and La/SSB, mediate cardiac inflammation and fibrosis, 
ultimately leading to fetal heart block.3  
Although the prevalence of congenital heart block (CHB) is only 2% in mothers 
with autoantibodies, the risk of recurrence is 17-18%, suggesting women who have 
previously given birth to children with cardiac NL are at highest risk of subsequent 
pregnancy complications related to CHB during a subsequent pregnancy.4 One study 
found that higher levels of anti-Ro antibodies, rather than simply their presence, were 
more predictive of fetal risk for developing cardiac NL.5 Consequently, research on 
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therapeutic prevention of cardiac NL has focused on reducing autoantibody levels to slow 
the progression of disease.6 Since cardiac disease typically presents during 2nd and 3rd 
trimesters, a therapy aimed at decreasing these levels early in pregnancy is of particular 
interest.  
 
Statement of the Problem 
Recently, the prevalence of autoimmune lupus has increased. As a result, more women 
are experiencing obstetric complications associated with lupus, requiring specialized care 
to improve maternal and fetal outcomes. In particular, women who are autoantibody 
positive have an increased risk of developing cardiac NL during pregnancy with 
congenital heart block (CHB) which carries significant morbidity and mortality.7 
Although research has enabled clinicians to better understand the pathogenesis of cardiac 
NL, there is currently no effective treatment and only limited evidence regarding 
preventative therapy.1 
Due to the irreversible nature of cardiac damage in NL, treatment is aimed at 
preventing the progression of disease. In a study involving mice, maternal administration 
of intravenous immunoglobulin (IVIG) therapy was associated with reduced levels of 
pathogenic autoantibodies and, subsequently, decreased cardiac tissue damage in the 
fetus.8 While this study provided support for the use of IVIG therapy in prevention of 





IVIG therapy during the first trimester of pregnancy will lead to a greater mean reduction 
in maternal anti-Ro/SSA antibody concentration compared to a saline placebo group. 
 
Objectives and specific aims 
The aim of this study is to evaluate the efficacy of intravenous immunoglobulin therapy 
as a first trimester intervention to decrease the burden of maternal anti-Ro/SSA 
autoantibodies. Since the development of cardiac NL begins during 2nd and 3rd trimesters, 
an approach aimed at decreasing autoantibody levels earlier in pregnancy may slow the 
progression of disease. The goal of first trimester IVIG therapy would be to prevent 
placental transfer of autoantibodies with subsequent reduction in the concentration of 
fetal autoantibodies at the time of delivery.  
Specific aims: 
1. To quantify the change in concentration of maternal anti-Ro/SSA autoantibodies 
as a result of maternal IVIG administration 
2. To quantify the reduction in the recurrence of fetal heart block as a result of 
maternal IVIG administration 




REVIEW OF THE LITERATURE 
Overview 
Systemic Lupus Erythematosus  
Systemic Lupus Erythematosus (SLE) is an inflammatory autoimmune disease of 
unknown cause that is often characterized by periods of spontaneous remission and 
relapses. While both men and women can be affected by lupus nearly 85% of patients are 
women, with most cases occurring between menarche and menopause.9 This suggests 
that hormones may contribute to the development of lupus in addition to genetics and 
environmental exposure. The overall prevalence of lupus in the United States ranges from 
20 to 150 cases per 100,000 with rates 2 to 3 times higher in African American and Asian 
populations compared to Caucasians.10 Additionally, African American and Asian 
patients experience more severe disease, which typically progresses faster than among 
Caucasian patients.10 While the cause of the discrepancy among races is unknown, it is 
thought that the increased prevalence is due to genetics and the increased severity of 
disease is partly due to environmental exposures.10  
 Although the etiology of lupus is unknown and likely multifactorial, the clinical 
manifestations of the disease are mediated by autoantibody formation and deposition of 
immune complexes throughout the body. Initially, patients present with nonspecific 
symptoms such as fatigue, fever, arthralgia and weight changes.11 Cutaneous findings 
associated with lupus can vary tremendously from oral mucosal lesions to the 
pathognomonic butterfly rash reported in 30% of patients.11 Many patients also 
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experience photosensitivity, an inflammatory discoid rash, alopecia and Raynaud 
phenomenon, which results in decreased blood flow to extremities.11 Although the 
clinical heterogeneity of lupus poses a challenge for many clinicians, the American 
College of Rheumatology developed a set of guidelines, requiring that a patient satisfy at 
least four of 11 criteria (Table 1) to be diagnosed with systemic lupus erythematosus.12  
Table 1. American College of Rheumatology Criteria for the Classification of 
Systemic Lupus Erythematosus12. IgG, immunoglobulin G; IgM, immunoglobulin M; 
LE, lupus erythematosus; Sm, smith; VDRL, venereal disease research laboratory 
1.  Erythema Malar  
2.  Discoid Lupus 
3.  Photosensitivity  
4.  Oral Ulcers 
5.  Arthritis 
6.  Serositis (pleuritis or pericarditis) 
7.  Nephropathy (persistent proteinuria greater than 0.5 g/day 
and/or glomerular hematuria) 
8.  Neurological disorders (convulsion or psychosis) 
9.  Hematologic disorders (hemolytic anemia, leucopenia, 
thrombocytopenia) 
10.  Immune disorder (presence of LE cells, anti-DNA or anti-
Sm antibodies, false positive VDRL test, anticardiolipin 
IgG or IgM antibodies, lupus anticoagulant) 
11.  Antinuclear Antibody (ANA) 
 
In addition, routine laboratory tests, including serologic testing to detect various 
antibodies specific to lupus, a complete blood count differential indicating possible 
anemia, leukopenia or thrombocytopenia, and a urinalysis, may further support the 
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diagnosis of lupus. In particular, antinuclear antibody (ANA) is positive in nearly all 
lupus patients at some point during the disease with a sensitivity approaching 100%. If 
the ANA is positive, additional laboratory testing is used for further confirmation, 
including anti-dsDNA, anti-Sm, Ro/SSA, La/SSB and U1 ribonucleoprotein.9  
Advancements in diagnostic testing have enabled physicians to identify milder 
cases of lupus, contributing to improved patient survival. One study reported a 5-year 
survival rate of only 50% among lupus patients from 1949 to 1953. Studies since the mid-
1970s had shown the 5-year survival rate to have increased to above 90% with a 15 to 20-
year survival rate around 80%.10 There reductions in mortality are likely due to both 
earlier diagnosis of lupus and improved treatment. As patients are living longer with 
lupus, they are also experiencing more severe complications as a result of disease 
progression. Most notably, the kidney is the most common visceral organ involved in 
lupus complications with 50% of patients presenting with clinical nephritis. The onset of 
glomerular disease can be asymptomatic and occur as early as one year into the disease. 
Thus, periodic screening with urinalysis is essential in lupus patients.11 In addition, 
patients with lupus nephritis have an increased incidence of hospitalized infections 
compared to lupus patients without nephritis, leading to higher mortality rates.13 
Another serious complication of SLE is coronary artery disease due to accelerated 
atherosclerosis, a significant cause of morbidity and premature death in lupus patients 
living into their 40s.14 The exact pathogenesis of accelerated atherosclerosis in lupus is 
unknown. However, it is believed to be caused by inflammation and immune complex 
deposition on blood vessels, which results in an increased risk of coronary artery 
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disease.14 There are additional SLE complications, including endocrine, hematologic, 
pulmonary and neuropsychiatric manifestations, each requiring careful observation from 
a team of clinicians.  
The management of lupus during pregnancy is especially challenging in 
autoantibody positive mothers who carry an increased risk of neonatal lupus syndrome. 
Although the incidence of lupus among pregnant women ranges from 1:660 to 1:2,952, 
the rates of lupus flares during pregnancy can increase to 25-65%.12 It is hypothesized 
that elevated levels of estrogen during pregnancy can exacerbate lupus. However, it can 
be difficult to clinically distinguish disease flares from normal pregnancy as the 
symptoms of both often mimic one another. Of note, patients with increased lupus 
activity 6 to 12 months prior to conception also have a higher risk of developing disease 
flares during pregnancy.12 One study assessed the impact of increased lupus activity on 
obstetric outcomes, finding that increased lupus activity resulted in higher rates of 
preterm deliveries and fetal loss.15 More specifically, higher disease activity during the 
first trimester of pregnancy led to a 3-fold increase in the rate of miscarriages with less 
than 1/3 of high-activity lupus patients reaching full-term delivery.15 Thus, appropriate 
management of lupus during the first trimester can improve the success of the pregnancy. 
Lastly, mothers who are positive for anti-Ro/SSA or anti-La/SSB antibodies carry an 
increased risk of neonatal lupus syndrome, which can ultimately lead to a more severe 
complication, congenital complete heart block.  
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Neonatal Lupus Syndrome  
Neonatal lupus syndrome is a rare acquired autoimmune disorder in which passive 
transfer of autoantibodies from the mother cause a variety of clinical symptoms in the 
fetus. Symptoms range from transient dermatological findings to irreversible cardiac 
complications, such as congenital heart block. Neonatal lupus syndrome is uncommon, 
occurring in only 1 out of 20,000 live births to lupus mothers with lupus. However, there 
is significant morbidity and mortality associated with the diagnosis, thus making it an 
important consideration in lupus pregnancies.2 
The most important risk factor for the development of neonatal lupus (NL) is the 
presence of maternal anti-Ro autoantibodies with virtually all neonatal lupus pregnancies 
testing positive for these antibodies.14 Other proposed risk factors for the development of 
NL include maternal hypothyroidism and fetal genetic polymorphisms. A 2006 study 
found that anti-Ro autoantibody positive mothers with hypothyroidism had a 9-fold 
increased risk of having a child with NL compared to autoantibody positive women with 
normal thyroid function.16 This study supports screening women with anti-Ro antibodies 
for hypothyroidism, as they may be at increased risk. Similarly, results from a Swedish 
study identified two genetic alleles, HLA-DRB1*04 and HLA-Cw*05, associated with an 
increased risk of developing NL.17 While the exact etiology of NL is unclear, many of the 
clinical manifestations can present similar to adult lupus.  
Symptoms of neonatal lupus range from hepatobiliary and hematologic disease to 
cutaneous and more commonly cardiac involvement. In cutaneous NL, lesions are 
characteristically erythematous macules that appear days to weeks after birth, most 
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commonly on the scalp and periorbital area.2 The histology of these lesions closely 
resemble those seen in adult subacute cutaneous lupus.2 Fortunately, the rash seen in 
neonatal lupus is self-limiting, usually resolving with clearance of antibodies by 6 to 8 
months of life and only requiring topical steroids for management of symptoms.2 In 
addition to cutaneous findings, there may be transient hepatic and hematologic 
involvement that also resolves with clearance of anti-Ro autoantibodies. The prevalence 
of hepatobiliary disease has increased in recent years, occurring in about 10% of patients 
with NL.2 Characteristics of hepatic involvement include elevated liver enzymes, 
transient hyperbilirubinemia, cholestasis and hepatitis. Similarly, NL with hematologic 
involvement typically presents during the infant’s first or second month of life with the 
symptoms of thrombocytopenia, anemia and neutropenia.2 The pathogenesis of 
neutropenia involves antibody cross reactivity in which maternal autoantibodies bind 
neutrophils, which results in decreased production of neutrophils.2 In summary, transient 
manifestations of NL, including cutaneous, hematologic and hepatobiliary disease, tend 
to resolve with the clearance of anti-SSA/Ro antibodies, providing additional support for 
the hypothesis that autoantibodies play a pathogenic role in the development of NL.  
Cardiac Neonatal Lupus 
The most serious complication of NL is cardiac NL. In the past, congenital heart block 
(CHB) was the only recognized cardiac abnormality in NL. However, with the 
development of a Research Registry for Neonatal Lupus, clinical researchers have 
identified a variety of other cardiovascular abnormalities. These abnormalities include 
structural defects and diffuse myocardial disease, which can be seen in the absence of 
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conduction abnormalities. Structural abnormalities associated with cardiac NL include 
persistent ductus arteriosus, septal defects and various valvular diseases.4 While the 
heterogeneity of cardiac NL can pose a challenge for clinicians, research has shown that 
earlier diagnosis and intervention is the best approach to optimize both maternal and fetal 
outcomes.  
Cardiac NL commonly involves injury to the conduction system, which can result 
in first, second, or third-degree heart block. The pathophysiology of heart block in 
cardiac NL patients is believed to be due to autoantibody-mediated damage of 
cardiomyocytes but the exact mechanism of tissue injury remains an area of 
investigation.4 It is unclear precisely how extracellular maternal antibodies react with 
intracellular SSA/Ro and SSB/La antigens. One hypothesis is that apoptosis of 
cardiomyocytes causes a shift of antigens to the cell surface where they are exposed to 
circulating antibodies.4 An alternative hypothesis is that maternal antibodies bind 
specifically to L-type calcium channels on fetal heart tissue, causing calcium 
dysregulation which ultimately leads to apoptosis.4 Both theories suggest some trigger for 
apoptosis that leads to activation of macrophages, initiating an inflammatory cascade that 
replaces the atrioventricular node with fibrotic tissue.4  
It is important to note that the presence of autoantibodies alone cannot predict the 
development of CHB and it is unclear why NL develops in some, but not all, antibody-
exposed fetuses. Among mothers who are autoantibody positive, only 2% give birth to 
children with cardiac NL.3 There has been recent evidence to suggest that the 
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concentration of maternal antibodies, rather than their presence, is more strongly 
associated with the of developing cardiac NL.5  
While maternal autoantibodies begin crossing the placenta as early as 11 weeks 
gestation, they are the most abundant in fetal tissue between 18 and 24 weeks and, thus, 
cardiac NL is typically diagnosed during the 2nd and 3rd trimesters.4 During this high risk 
period, normal sinus rhythm can progress to complete heart block within one week.18 
Therefore, early surveillance with frequent fetal echocardiography is necessary in 
autoantibody positive pregnancies. With improved accuracy in diagnostic tools and the 
potential for earlier interventions, the American Heart Association suggests beginning 
fetal echocardiography assessments as early as 16 weeks.19 In higher risk women, 
including those with a previously affected child, imaging assessments are recommended 
weekly and should be continued through 28 weeks gestational age.19  
The mortality rate for complete CHB in neonatal lupus ranges from 4% to 29% 
with approximately 15% of infants dying before 3 months of age.4 Generally, CHB 
children with structural heart disease have a higher mortality than those without structural 
heart disease.4 Of those newborns surviving, greater than 65% require permanent 
pacemakers, which increases their risk of additional cardiac complications.4 Although the 
overall risk of cardiac NL is only 2% in autoantibody positive mothers, the estimated rate 
of recurrence is nearly 17% and even higher following two consecutive children with 
cardiac NL.3 This provides evidence to a possible genetic etiology for the development of 
cardiac NL, as well as identifies a high-risk population of patients in need of early 
preventative therapies.  
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The suggested treatment for cardiac NL depends on the degree of heart block. 
Typically, patients are managed medically with fluorinated steroids, sympathomimetics 
for bradycardia and hydroxychloroquine. In first degree heart block, however, treatment 
is controversial. A study found that fetal AV prolongation did not predict progressive 
heart block and, in many cases, spontaneously resolved to normal sinus rhythm.20 
Moreover, there is inconsistent evidence regarding the benefit of glucocorticoids in the 
treatment of first degree block and thus, some physicians will monitor the patient while 
others will treat with glucocorticoid therapy daily. Unlike first degree block, second 
degree almost always progresses to CHB and requires medical intervention with 
glucocorticoids.21 The goal of glucocorticoids in second degree heart block is to decrease 
inflammation and, most importantly, prevent irreversible third degree block.21 
Unfortunately, there is no pharmacological therapy that can reverse third degree CHB 
and treatment is limited to sympathomimetics for fetal bradycardia and postnatal 
pacemaker implantation.22  
The substantial morbidity and mortality associated with CHB has driven research 
into fetal preventative therapy to stop the progression of cardiac fibrosis. There have been 
some studies showing promising therapeutic interventions targeting the pathogenesis of 
cardiac NL. The use of hydroxychloroquine (HCQ), an anti-malarial drug, has been 
associated with a 64% decrease in recurrence of cardiac NL as it inhibits toll-like 
receptors involved in inflammation affecting the AV node.23 Another target for fetal 
intervention in cardiac NL is anti-Ro and La antibodies, which are required for disease 
development. Since cardiac complications from NL generally don’t occur until the 2nd 
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and 3rd trimesters, it is hypothesized that an intervention during 1st trimester that 
decreases the level of autoantibodies present may decrease the risk of developing cardiac 
NL.  
Currently, there are two proposed treatments, plasmapheresis and intravenous 
immunoglobulin (IVIG) therapy, that could potentially decrease the concentration of 
autoantibodies present in fetal circulation. Plasmapheresis has never been used 
independently of steroids, is costly and time consuming, and, therefore, may not be an 
optimal intervention for the prevention of cardiac NL.18 In contrast, IVIG therapy is safe, 















Researchers have begun exploring the use of prenatal IVIG therapy as they’ve gained a 
better understanding of the pathogenesis of cardiac NL. While studies have been 
published that highlight the role of autoantibodies in the development of cardiac NL, 
there is limited research exploring the use of IVIG therapy as preventative intervention 
during first trimester.  
An important study that helped establish the role of autoantibody concentration, 
specifically anti-Ro and La, in the pathogenesis of cardiac NL was a prospective 
observational study by Jaeggi et al. in 2010.5 Prior to this study, researchers had 
documented an association between maternal autoantibodies and the development of 
CHB, however, little was known why only some and not all offspring were affected. 
Thus, this study aimed to determine whether maternal autoantibody concentrations, rather 
than simply their presence, could better predict fetal risk of developing cardiac NL. The 
study included all cases of autoantibody positive mothers who were referred for serial 
fetal echocardiography or cardiac related complications since 2000 at the Hospital for 
Sick Children in Toronto. Participants were prospectively followed throughout pregnancy 
and researchers collected antibody levels before referral, at the beginning of the study and 
when possible, in live infants.  
The results of this study confirmed the hypothesis that elevated antibody levels 
were associated with fetal cardiac damage in NL. All cardiac complications, including 
heart block, myocardial dysfunction, pericardial effusion and endocardial fibroelastosis, 
were seen exclusively in mothers with moderate (≥ 50 U/ml; 15%) or high (≥ 100 U/ml; 
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85%) anti-Ro levels with no complications observed when antibody levels were below 50 
U/ml.5 The odds ratio of developing cardiac complications in fetuses exposed to anti-Ro 
levels ≥ 50 U/ml was 7.8 compared to fetuses exposed to a concentration below 50 
U/ml.5  
While these findings demonstrate an association between the concentration of 
anti-Ro antibodies and cardiac NL, this study is limited in establishing causality. 
Additional studies are necessary to provide direct evidence that anti-Ro antibodies are the 
cause of cardiac NL during pregnancy. However, with new insight into the potential 
pathogenesis of cardiac NL, researchers were able to explore the use of therapies, 
including HCQ, plasmapheresis and IVIG, to reduce the concentration of these 
pathogenic autoantibodies.  
Hydroxychloroquine, an antimalarial medication, is commonly prescribed in 
patients with lupus, however, its safety during pregnancy remains controversial. The 
Federal Drug Administration (FDA) classifies anti-malarial drugs, including HCQ and 
chloroquine, as category C drugs in pregnancy. Thus, their use has been associated with 
adverse effects on the fetus in animal studies, though there have been no adequate studies 
in humans to assess potential risks.24 In particular, HCQ must be carefully monitored 
during pregnancy as it can rapidly cross the placenta and accumulate to concentrations 
equivalent to maternal blood concentrations.25 Furthermore, the half-life of HCQ can 
extend beyond 3 months with selective accumulation in the melanin structures of the fetal 




One study evaluating the use of HCQ in reducing recurrent cardiac NL found a 
64% decrease in recurrence in those exposed to HCQ compared to those unexposed.23 
This was a retrospective cohort study assembled from international databases that 
recruited anti-SSA/Ro positive women with a previous CHB pregnancy. Participants 
reported HCQ exposure if they took at least 200 mg per day by 10 weeks of gestation and 
continued throughout pregnancy. Of the 257 pregnancies, only 40 women reported taking 
HCQ. Participants reported decreased use following case reports of auditory and retinal 
toxicity associated with HCQ. Although these results suggest a potential benefit with 
HCQ administration, the retrospective design and lack of randomization limits the study’s 
ability to establish causality. Thus, further prospective studies are necessary to confirm 
these findings.23 
Plasmapheresis, one approach to reduce the concentration of autoantibodies in 
high risk pregnancies, is costly and time consuming, and, therefore, has a limited role in 
the management of cardiac NL. Furthermore, there have been no controlled experiments 
on the use of plasmapheresis in preventing cardiac NL.18 Of the few case reports that 
analyzed the role of plasmapheresis, there have been several that reported no benefit in 
treating previously developed heart block, while others showed a benefit when used in 
combination with other treatment methods. Ruffatti et al described two cases where a 
fetus with 2nd degree heart block was treated with a combination of plasmapheresis, 
dexamethasone and IVIG. Both children improved to first degree heart block at delivery, 
however, it is unclear which therapy or combination of therapies led to these findings.18 
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The effectiveness of maternal IVIG to prevent fetal CHB was first reported in 
animal models. A study by Kaaja and Julkunen evaluated the role of IVIG therapy in 
blocking antibody transfer across the placenta, and, consequently, cardiac deposition in 
mice. Time-mated pregnant mice were injected with either 1.5 gm/kg of IVIG or saline at 
day 14 of gestation and 0.5 ml of human anti-Ro/La serum on day 15. Researchers 
measured maternal and fetal autoantibody levels and analyzed cardiac pathology 
following death at day 17 of gestation. Fetal:maternal ratios of anti-Ro 52, anti-Ro 60 and 
anti-La levels were significantly lower in fetuses of mothers exposed to IVIG therapy 
compared to fetuses receiving saline (Figure 1). In addition, the IVIG treated mice had 
less cardiac tissue damage with 19% fewer IgG complexes compared to the control.8  
These results suggest maternal administration of IVIG therapy inhibited the transfer of 
pathogenic autoantibodies and subsequently, decreased the amount of cardiac damage.  
 
 
Figure 1: Fetal/Maternal Antibody Ratio in IVIG-Exposed Fetus vs. Control. 
Adapted from Kaaja and Julkunen.8 
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It was not reported, however, whether the concentration of maternal 
autoantibodies decreased following IVIG therapy. IVIG therapy is believed to prevent 
cardiac tissue damage through three specific mechanisms: accelerated elimination of 
maternal autoantibodies through IVIG saturation of FcγRn; decreased placental transport 
of antibodies; and modulation of macrophage signaling, leading to decreased 
inflammation and fibrosis.7 This study provides evidence supporting the use of IVIG 
therapy in decreasing placental transport of antibodies in mice but does not evaluate 
changes in the concentration of maternal autoantibodies.  
Another murine model study evaluated IVIG therapy in fetal and neonatal 
alloimmune thrombocytopenia, which carries a similar pathogenesis to cardiac NL.28 In 
fetal and neonatal alloimmune thrombocytopenia, maternal antibodies cross the placenta 
and cause fetal platelet destruction, leading to a life-threatening bleeding disorder. 
Results showed that administration of maternal IVIG therapy alleviated symptoms 
associated with alloimmune thrombocytopenia and decreased the concentration of both 
maternal and fetal antibodies.28 The potential for IVIG therapy to decrease maternal 
antibody concentrations extends beyond this study and may have broad implications for 
other antibody-mediated diseases that develop during pregnancy.   
In an attempt to replicate similar results in humans, the PITCH, Preventative IVIG 
Therapy for Congenital Heart Block, study was designed. This was a prospective 
multicenter open-label study between January 2007 and January 2009 that recruited 20 
women who were autoantibody positive, had a previous child with CHB and/or NL rash, 
and were currently less than 12 weeks pregnant with a normal fetal heart beat and 
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structure.7 Mothers were given IVIG infusions of 400 mg/kg over 3-4 hours every three 
weeks starting at week 12. Fetal echocardiograms were performed weekly between 16 
and 26 weeks of gestation. Both maternal and cord blood antibody samples were 
collected but only changes in maternal antibody titers were statistically analyzed. The 
primary outcome of the study was 2nd or 3rd degree AV block with secondary outcomes 
including sustained 1st degree AV block, transiently prolonged PR interval, signs of 
myocardial injury, endocardial fibroelastosis, fetal death, NL rash, premature birth, birth 
weight lower than the 10th percentile for gestational age, and fluid collection consistent 
with hydrops. The study, however, was terminated early due to the pre-determined 
stopping rule of three cases of advanced CHB. These cases were detected at 19, 20 and 
25 weeks. Two of these mothers had received only three doses of IVIG therapy before 
progressing to CHB and the last mother had four doses. Unlike the murine data reported 
above, there were no significant changes in maternal antibody titers over the course of 
therapy, which could be attributed to the low dose of therapy used or the small sample 
size.7  
The main limitation of this study was the open label design and, additionally, a 
small sample size. The trial utilized Simon’s 2-stage optimal design to allow for early 
stopping if 3 or more mothers had children with 2nd or 3rd degree CHB.7 During the first 
stage, 19 subjects were recruited and followed to evaluate for cardiac disease. If fewer 
than 3 pregnancies developed advanced CHB, then 35 mothers would be enrolled in the 
second stage for a total of 54 participants. At the end of both stages, treatment would be 
considered efficacious if fewer than 6 women developed 2nd or 3rd degree CHB.7 Due to 
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the early termination of this study, only 20 mothers completed the IVIG protocol and, 
thus, this study is limited by the small sample size.    
 In addition, the PITCH study used a dose of IVIG therapy below that required to 
see a clinically relevant effect. Anti-inflammatory effects of IVIG therapy have been 
reported using 1-3 gm/kg, whereas the PITCH study only used 0.4 gm/kg.7 Thus, it is 
unknown if IVIG therapy at a higher dose could decrease the concentration of maternal 
antibodies below that needed to prevent fetal cardiac injury. Lastly, of the 20 subjects, 16 
children did not develop neonatal lupus at birth and there were no safety issues reported. 
This confirms the safety of IVIG therapy during pregnancy and supports the use of higher 
doses.  
 Although researchers have a better understanding of the pathogenesis of cardiac 
NL, there is currently no established treatment for CHB. Evidence from animal models 
supports the use of IVIG therapy in reducing cardiac damage in antibody-exposed 
fetuses, however, there is limited evidence from human studies to confirm these findings. 
Therefore, a pilot study evaluating the change in concentration of maternal anti-Ro/SSA 
antibodies following IVIG administration may guide new approaches in the prevention of 








The proposed study will be a pilot, double-blind, randomized control trial assessing the 
effect of IVIG therapy on the change in concentration of maternal autoantibodies 
throughout pregnancy. The experimental group will receive IVIG therapy throughout 
pregnancy and the control group will receive a saline placebo. 
 
Study population and sampling 
The study population for this trial will include insured anti-Ro/SSA positive women with 
a formal diagnosis of rheumatologic disease who are currently ≤8 weeks pregnant. 
Participants must have an intrauterine pregnancy with a normal fetal heart beat (120-160 
bpm) and no cardiac abnormalities.29 Documentation of positive maternal anti-SSA/Ro 
autoantibodies will be defined as any serum value ≥ 8 U/ml.5  
Participants must have a formal prior diagnosis of rheumatologic disease from a 
licensed physician which may include: SLE with the patient meeting at least 4 criteria 
from the American College of Rheumatology, Sjogren’s syndrome, or undifferentiated 
autoimmune syndrome (UAS), if neither criteria are met.7 Anti-Ro autoantibodies are 
present in women diagnosed with SLE, Sjogren’s Syndrome or Undifferentiated 
Autoimmune Syndrome (UAS), in which they meet neither criteria.4 The latter two 
rheumatologic diseases are similarly associated with passive autoantibody transfer and 
the development of NL. There will be no exclusions for patients based on age, ethnicity 
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or severity of rheumatic disease and patients may participate even if they are clinically 
asymptomatic at the time of enrollment.  
For this pilot study, it is feasible to enroll approximately 40 subjects per year in 
Boston. There are approximately 7,800 pregnancies in Boston per year30 with 1-2% 
testing positive for anti-Ro/SSA antibodies.31 Thus, around 120 pregnant women per year 
will test anti-Ro/SSA antibody positive in Boston, and, therefore, an enrollment goal of 
40 subjects per year is feasible. The study will continue for three years and enroll a total 
of 120 participants with 60 in each arm. Assuming an alpha level of 0.05, this study will 
have 80% power to detect a medium effect size of 0.52 standard deviations of the mean 
change in autoantibody concentrations.33 
 
Treatment 
Participants will be randomized using the stratified randomization method to achieve 
balance among subjects’ baseline characteristics, including maternal age, race and report 
of a previous CHB pregnancy.34 Both clinicians administering IVIG therapy and 
participants will be blinded to treatment.  
Subjects randomly allocated to the experimental arm will receive 2 g/kg of IVIG 
therapy every three weeks, starting at gestational week 10 and continuing through week 
24, for a total of six treatments. The IVIG dose used in this study is within the reported 
range of an appropriate therapeutic dose, 1-3 gm/kg body weight.7 Additionally, 
participants will receive treatment every 3 weeks, which is the same frequency used in 
the PITCH study.7 Subjects randomly assigned to the placebo-control group will receive 
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saline infusions at the same time intervals. Both treatments will take place over the 
course of each pregnancy and all participants will continue to attend prenatal visits as 
recommended by their obstetrician.  
Treatment sessions will take approximately 3-4 hours and occur every 3 weeks to 
ensure IVIG is administered safely and that serum concentrations remain appropriate 
based on the 21-day half-life of IVIG.35 During this time, clinicians will also inquire 
about any side effects. If participants experience mild side effects, such as headache, 
myalgia, fever, chills, nausea, vomiting or changes in blood pressure and heart rate, they 
will be monitored until resolution of symptoms.36 If symptoms do not resolve within one 
week, subjects will discontinue treatment. Mothers who report any symptoms of severe 
reactions including anaphylactic shock, meningitis, oliguria or stroke, will immediately 
discontinue treatment.36 
  
Study variables and measures 
During enrollment, participants will complete a questionnaire focused on environmental 
and lifestyle factors including: maternal age, race, BMI, average sun exposure, previous 
maternal infections, stressful events and reports of a previous child developing CHB.37  
 At the beginning of the study, blood samples from all participants will be 
analyzed in the laboratory by ELISA7 to record a baseline anti-Ro/SSA antibody 
concentration. ELISA is a safe, rapid, specific and sensitive test that is readily accessible 
in all laboratories.38 Subsequent serum samples will be collected before each IVIG or 
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saline infusion at weeks 10, 13, 16, 19, 21 and 24 with a final sample taken at the time of 
delivery.  
 Secondary outcomes include fetal 1st degree heart block defined by PR 
prolongation > 150 ms, 2nd degree heart block and CHB.7 Serial fetal echocardiograms 
will be obtained weekly from 16 weeks until 26 weeks and biweekly, thereafter, as 
outlined in the PRIDE study, to evaluate for cardiac abnormalitiese.39 Results will be 
interpreted by Maternal-Fetal Medicine (MFM) specialists and those who exhibit signs of 
progressive cardiac damage will stop treatment. 
 
Recruitment 
In an effort to educate practicing physicians who may have anti-Ro positive patients, 
several hospital information sessions will be held throughout Boston to inform physicians 
of the study. Rheumatologists and Obstetricians practicing in the Boston area will refer 
patients who are anti-Ro antibody positive and who are currently pregnant or considering 
becoming pregnant for participation in this study. There will be a fifty-dollar incentive 
for subjects who enroll in the pilot study to reduce loss to follow-up and achieve 
recruitment goals. Following referral, potential subjects will be evaluated by clinical 
members of the study to ensure they meet appropriate criteria. Individuals who meet the 
inclusion criteria will be consented to participate in the study and followed by Maternal-





Prior to the start of the study, participants will complete an electronic lifestyle 
questionnaire using a portable tablet during an initial assessment visit with clinical 
researchers. Following initial screening, participants will provide blood samples to 
determine a baseline serum autoantibody concentration before beginning their assigned 
treatment. Anti-Ro/SSA antibody levels will also be drawn before each treatment session 
and again at the time of delivery. To assess for fetal cardiac abnormalities, a secondary 
outcome, participants will receive fetal echocardiograms weekly from 16 weeks until 26 
weeks and biweekly after 26 weeks. 
 
Data analysis 
Patient demographics will be analyzed using descriptive statistics to summarize the data. 
Maternal age and BMI will be reported using mean and standard deviation while race, 
average sun exposure, previous maternal infections, stressful evens and reports of 
previous child developing CHB will be reported using proportions.  
The difference between the concentration of maternal antibodies at the beginning 
of pregnancy and at the time of delivery will be calculated for each subject. The mean 
change in concentration of maternal anti-Ro/SSA antibodies following IVIG therapy will 
be compared to the change observed in the placebo-control group using the Student’s T 
test. The Chi-square test will be used to quantify any difference in secondary cardiac 
outcomes, following IVIG therapy or saline infusions. Lastly, to evaluate potential 
maternal risk factors influencing the development of CHB, a logistic regression analysis 
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will be used. This is a predictive analysis used to describe the relationship between 
maternal risk factors (age, race, BMI, average sun exposure, previous maternal infections, 
stressful events, reports of a previous child developing CHB) and the development of 
CHB.40 Other maternal and fetal blood samples collected will not be analyzed, however, 
may be utilized in subsequent secondary analysis.  
 
Timeline and resources 
Prior to beginning the study, 6 months to 8 months will be allowed for IRB approval, 
planning and recruitment of potential subjects. Thus, this study will begin in the Fall of 
2019. The timeline of intervention will occur over nine months of pregnancy. 
This study will last approximately 3 years, during which 40 subjects will be 
recruited per year for a total of 120 participants. At the conclusion of the study, estimated 
to be at the end of year 2021, 3 months will be required for data analysis and a 
manuscript of study findings will be prepared.  
The study will require 6 clinicians, including 3 who are trained in administering 
IVIG therapy and 3 MFM specialists who can monitor patients throughout their 
pregnancy, including fetal cardiac monitoring with serial echocardiography. Four trained 
research staff members will oversee the recruitment process and assist with coordination 
of participants. This study will require assess to laboratory services, including 1 
laboratory technician to perform an ELISA assay for detection of anti-Ro/SSA antibodies 
in all subjects. Lastly, a statistician will be required for complete data analysis at the 




Institutional Review Board 
The proposed study requires an IRB application for full-board review. This study is no 
more than minimal risk but since the participants are a protected population it will require 
review by the full board. There should be no harm endured to the fetus. Upon approval by 






IVIG therapy has the potential to decrease maternal autoantibody burden throughout 
pregnancy with subsequent reduction in fetal risk of cardiac NL. Although the prevalence 
of cardiac NL is relatively low, the potential morbidity and mortality associated with the 
diagnosis is substantial. More than half of children born with CHB require cardiac 
pacemakers because there is no effective treatment for the disease.41 However, recent 
evidence regarding the pathogenesis of maternal autoantibodies in the development of 
cardiac NL has enabled researchers to explore targeted therapies in utero. In particular, 
IVIG therapy has proven to be beneficial in decreasing cardiac damage in anti-Ro/SSA 
antibody positive mice and has been found to be safe in pregnant women.8,7 The purpose 
of this study is to compare the change in maternal antibody concentration throughout 
pregnancy following IVIG therapy compared to the control group.   
 A double-blinded placebo-controlled randomized trial is appropriate as it provides 
strong evidence toward establishing causality between IVIG therapy and the change in 
concentration of maternal autoantibodies throughout pregnancy. This study design is 
clinically acceptable in this population of patients as both IVIG administration and 
normal saline infusions are safe during pregnancy. Randomization also minimizes 
allocation and selection bias and thus, provides the most unbiased method for assessing a 
clinically significant outcome following IVIG therapy during pregnancy. While there are 
certainly benefits to this study design, any intervention during a high-risk pregnancy does 
not come without its own limitations.   
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 Although analyzing fetal autoantibody levels may better predict the development 
of fetal cardiac NL, this technique is unsafe and, thus, will not be used during this study. 
Sampling fetal cord blood throughout pregnancy would require ultrasound guidance and 
carries a 1% risk of fetal loss.42 While the risk is relatively low, it would not be indicated 
early in pregnancy or more than once throughout pregnancy. Thus, measuring maternal 
autoantibody concentrations is a safer approach to assess the benefit of IVIG therapy in 
reducing pathogenic levels.   
Lastly, this study is limited by its sample size. As with any pilot study, the sample 
size used in this study may may result in not being properly powered to detect a true 
difference between the IVIG treated group and the saline placebo group.43 Additionally, 
there still may be demographic differences between the two arms despite using a 
stratified randomization method. Although there are limitations to pilot studies, it will 
provide beneficial information regarding feasibility and modifications necessary to plan 
larger randomized controlled trials exploring IVIG as an intervention.  
	 		
Summary 
Although the development of cardiac NL is relatively uncommon, the population of 
women at risk for developing fetal heart block is significant. Approximately 1-2% of 
pregnant women test positive for anti-Ro/SSA antibodies, even if they are clinically 
asymptomatic.34 Recently, there has been evidence to suggest that the concentration of 
maternal antibodies correlates with the risk of developing cardiac complications in NL. 
As lupus is most often diagnosed in women during their reproductive years, management 
during pregnancy is especially important to decrease the risk of poor fetal outcomes.  
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 Currently, there is no treatment to reverse CHB and most children experience life-
long complications if they survive past delivery. Thus, a therapy aimed at preventing the 
progression of cardiac disease by eliminating or reducing the concentration of 
autoantibodies may be beneficial. The purpose of this study is to quantify any change in 
the concentration of maternal autoantibody levels following several administrations of 
IVIG therapy during pregnancy. This study could potentially add to the evidence 
supporting the use of IVIG therapy as an intervention in preventing the progression of 
cardiac disease in NL.  
 The secondary outcomes of this study may also enable researchers to better 
predict the development of fetal heart block through identification of maternal risk 
factors, such as maternal age, race, BMI, average sun exposure, previous maternal 
infections, stressful events and reports of a previous child developing CHB. 
Retrospective studies have found infections and stressful events to be more frequent in 
CHB-affected pregnancies with outdoor activity proving to be protective in the 
development of CHB.37  Additionally, the evaluation of fetal heart block through 
echocardiography will allow researchers to quantify any reduction in development of 
CHB with IVIG therapy compared to the control group.  
  
Clinical and/or public health significance 
The aim of this study is to evaluate the efficacy of IVIG therapy as preventative treatment 
in the development of CHB by reducing the concentration of maternal autoantibodies. 
Since the development of cardiac NL begins during the 2nd and 3rd trimesters, an 
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approach aimed at eliminating or decreasing autoantibody levels earlier in pregnancy 
may prevent the progression of disease. A therapy designed to inhibit the transfer of 
pathogenic antibodies across the placenta may prevent any cardiac damage in the fetal 
heart and guarantee a successful pregnancy. Therefore, designing a study to assess the 
potential benefit of IVIG therapy in human subjects is paramount.  
Current therapy for cardiac NL is costly and revolves around the use of cardiac 
pacemakers and medication targeting symptoms of heart failure. Moreover, neonates who 
require pacemakers experience more complications than older adults, including central 
venous obstruction, tricuspid valve abnormalities and infection.4 Approximately, 14% of 
adults born with CHB die from cardiac complications, which can occur at any age.4 Thus, 
the clinical impact of CHB is significant and can lead to various challenges both in 
neonates and later on in life. IVIG may provide clinicians a safe and cost-effective 
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